Dominican Society of Cardiology holds its 1st continuing medical education symposium

• Lectures and expert panels addressed ischaemic heart disease, heart failure and cardiac arrhythmias, and the New Cholesterol Roadmap 2022 was presented.

Santo Domingo. – The Dominican Society of Cardiology (SODOCARDIO) brought together 180 doctors at the Cardiovascular symposium “From ischaemia to heart failure”, with more than 15 speakers.

With the aim of strengthening the prevention and care of cardiovascular disease through activities and projects that promote scientific knowledge, studies and registries, as well as campaigns, meetings and congresses aimed at improving people’s cardiovascular health, SODOCARDIO brought together experts from different fields dedicated to preventing and mitigating heart conditions.

The organisers reported that the event was held at the Hotel Catalonia Santo Domingo, with the participation of specialists and opinion leaders.

“By holding events like this, we are enthusiastically seeking to promote scientific exchange between members and new generations in the field of cardiology,” said Dr. Rafaelina Concepción, president of SODOCARDIO.

The first part of the symposium addressed Precision Medicine for Cardiovascular Disease Risk and the Initial Invasive Strategy in Patients with Stable Coronary Disease, as well as New Imaging Strategies for Predicting Ischaemia, and Coronary Flow and Coronary Flow Reserve.

In addition, Dr. Rodrigo Alonso, a Chilean lipidologist and nutritionist and co-author of the 2022 cholesterol guideline, gave the keynote lecture “New Cholesterol Roadmap 2022”, presented at the World Congress of Cardiology 2022.

The final focus of the meeting was cardiac arrhythmias. The experts discussed Tachycardiomyopathy, an Underdiagnosed and Reversible Cause of Heart Failure, and the Management of Patients with Ventricular Arrhythmia and Prevention of Sudden Death.

The event was supported by EUROFARMA laboratories. Aware of the need for continuing medical education, the multinational pharmaceutical company, present in 21 countries with 10 production plants in Latin America, seeks to bring together the different players on relevant cardiology topics, investing in innovation and supporting prevention, care and innovative, effective treatments for cardiovascular disease.

---

About the Eurofarma Group

Eurofarma is a 100% Brazilian-owned multinational that, since 1972, has been recognised by the medical community and society for promoting access to health and quality of life with affordable, high-quality and innovative treatments.

For 50 years, the Eurofarma Group has operated in the health sector, producing and marketing products and services to improve people’s quality of life. With a diversified presence, it operates in all the main segments, such as Prescription, Over-the-Counter, Generics, Hospital and Oncology, as well as the export and contract manufacturing of medicines.

The Eurofarma Group is present in more than 20 countries, with 10 production plants in Latin America.

Find out more about AF Comunicación Estratégica and its clients